Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.31.1 (
micrococcal nuclease
)
2,818
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interleukin-2
(
IL-2
) responsiveness of T lymphocytes is controlled through transcription of the IL-2 receptor (IL-2R) alpha subunit by antigen and by
IL-2
itself.
IL-2
induces IL-2Ralpha transcription via an
IL-2
-responsive enhancer (IL-2rE), whose activity depends on the cooperative binding of
IL-2
-induced STAT5 to two sites and of constitutively active Elf-1 to a third one. Here we describe the changes in IL-2rE chromatin that occur in normal T lymphocytes upon activation of IL-2Ralpha expression. In cells induced to transiently express IL-2Ralpha with concanavalin A (which mimics antigen), none of the IL-2rE sites is occupied despite the presence of Elf-1 and STAT1, which bind to the IL-2rE in vitro. The two STAT binding sites are occupied rapidly upon
IL-2
stimulation, concomitantly with STAT5 activation. Occupation of the Elf-1 binding site is delayed, although Elf-1 concentration and binding activity are not modified by
IL-2
. Digestion of T-cell chromatin with DNase I and
micrococcal nuclease
shows that
IL-2
induces the appearance of nuclease-hypersensitive sites flanking the IL-2rE. Thus
IL-2
, in addition to activating STAT5, appears to regulate IL-2Ralpha transcription by making IL-2Ralpha chromatin accessible to transcription factors.
...
PMID:Interleukin-2 (IL-2) regulates the accessibility of the IL-2-responsive enhancer in the IL-2 receptor alpha gene to transcription factors. 1008 34